Objectives
==========

Post-traumatic stress disorder (PTSD) is a common psychiatric disorder that may occur following a range of experiences including witnessing life-threatening incidents such as in a war zone, natural disasters, terror attacks, and serious car accidents. Persistent avoidance of stimuli, slow responses (eg, feelings of isolation and loss of personal interests), re-experiencing the trauma (unavoidable recall of the traumatic event, nightmares), and increased autonomic stimulation (hyper activity, irritability, and sleep disorders) are the main symptoms of this condition, observable shortly after onset.[@b1-ndt-11-395] Whereas not everyone exposed to such life events develops PTSD, in the USA, it occurs among 10% of women and 5% of men who were previously exposed to such kind of live events.[@b2-ndt-11-395] Moreover, the life-time risk in the general population of developing at least one episode of PTSD is estimated to be 8%--9%.[@b3-ndt-11-395] In addition to flashbacks, nightmares are often reported by those suffering from PTSD. In this context, sleep disorders comprise about 70% of the complaints of patients with PTSD.[@b4-ndt-11-395],[@b5-ndt-11-395] They are also more likely to commit suicide than persons without PTSD.[@b6-ndt-11-395],[@b7-ndt-11-395] The risk of suicide among those with PTSD is higher for people reporting nightmares than for those who do not.[@b8-ndt-11-395] Accordingly, symptoms need to be recognized and treated appropriately if they are not to become persistent.[@b9-ndt-11-395] In addition, patients with PTSD are at high risk of developing comorbid psychiatric disorders such as mood, anxiety, and substance abuse disorders. Furthermore, the high chronicity, severity, and comorbidity of PTSD are associated with high levels of functional and psychosocial disability,[@b10-ndt-11-395] and also with dramatic impairments in memory and autobiographical memory.[@b11-ndt-11-395] Accordingly, in the present study, we investigated the influence of additional CBT on the autobiographical memory of patients with PTSD.

As regards treatment interventions, PTSD can be treated both pharmacologically and non-pharmacologically; that is, psychotherapeutically. Depending on symptom severity and comorbid disorders, pharmacological treatment typically involves administration of selective serotonin reuptake inhibitors (SSRIs), benzodiazepines, and antipsychotics. Diverse medication classes, including antidepressants, anticonvulsants, antipsychotics and antiadrenergic drugs have been used to treat PTSD. Thereby, antidepressants are the most used and prescribed medication for PTSD,[@b3-ndt-11-395] and SSRIs are the only class of medication approved for treatment of PTSD in the USA. SSRIs seem to be safer and better tolerated than other psychotropic medications and many of the clinical trials showed that there is evidence of best efficacy in reducing PTSD symptoms for this class of medication.[@b3-ndt-11-395] SSRIs have shown to be efficient in reducing symptom severity and in preventing PTSD patients from relapsing, although just a few patients (about 60%) respond to treatment and only approximately 20%--30% have been fully remitted.[@b12-ndt-11-395] SSRI paroxetine, for example, succeeded in effective reduction of symptoms of all three PTSD symptom clusters, namely re-experiencing of the trauma, increased arousal, and avoidance of situations that resemble the traumatic event.[@b10-ndt-11-395] Among the empirically-supported psychotherapeutic interventions are trauma-focused cognitive behavioral therapy (CBT), exposure-based therapy, eye movement desensitization and reprocessing,[@b10-ndt-11-395] stress inoculated training, and CBT.[@b12-ndt-11-395] Further, prolonged exposure is the most researched and best validated non-pharmacological treatment for PTSD.[@b3-ndt-11-395] In the present study, we focused on CBT.

Several placebo-controlled trials and meta-analyses support the view that these non-pharmacological treatments are effective in reducing PTSD symptoms.[@b13-ndt-11-395] International guidelines recommend non-pharmacological treatment for all PTSD patients as the first option (Polak et al[@b10-ndt-11-395]) and pharmacological treatment as a second option, but no consensus has been achieved on these alternatives so far.[@b3-ndt-11-395] More specifically, and contrary to Polak et al,[@b10-ndt-11-395] Ipser et al[@b14-ndt-11-395] concluded based on a Cochrane review that medication treatments can be effective in treating PTSD, and should be considered as a part of the treatment of PTSD, with the application SSRIs as first-line agents in the pharmacotherapy of PTSD. However, we also note that the Institute of Medicine Report concluded that there was no evidence that one of the several medication classes was effective for treatment of PTSD, while the UK National Institute for Clinical Excellence recommended in 2005 that medications should only be used as a second-line treatment for PTSD.[@b3-ndt-11-395] This may also be due to the much higher treatment costs for pharmacotherapies in comparison to psychotherapies, especially in relation to higher expected relapse rates with pharmacotherapies.[@b10-ndt-11-395] Moreover, the efficacy of pharmacological treatment for PTSD may also depend on the type of symptoms. On the other hand, and apparently paradoxically, Mellman et al[@b16-ndt-11-395] estimated that 77% of PTSD patients in a community-based sample received pharmacotherapy. This high rate for pharmacotherapy may reflect the low availability and accessibility of psychotherapy.[@b10-ndt-11-395] There is also some evidence that those patients who report more severe sleep difficulties have poorer treatment outcomes with psychotherapy.[@b3-ndt-11-395]

Last, combined pharmacotherapy and psychological therapies are especially recommended when patients have not responded to either intervention alone,[@b16-ndt-11-395] and this needs to be further examined in future research.[@b18-ndt-11-395],[@b19-ndt-11-395]

A further issue of PTSD regards memory performance, in that one of the most serious and frequent symptoms of PTSD is intrusive memories of the traumatic event.[@b20-ndt-11-395] Since PTSD symptoms often persist long after exposure to the traumatic event, researchers have given particular attention to memory as a key factor in the pathogenesis of the disorder.[@b22-ndt-11-395] Most strikingly, there is evidence that PTSD patients show difficulties in retrieval of autobiographical memories.[@b21-ndt-11-395] In addition, patients with PTSD tend to report more memories related to the traumatic event compared to people without PTSD.[@b20-ndt-11-395] They tend to exhibit difficulties in recalling specific memories; producing a so-called "overgeneralized" autobiographical memory.

Furthermore, it is not only autobiographical memories that are characterized by overgeneralization. Expectations that individuals with PTSD have about imagined future events are also characterized by overgeneralization.[@b20-ndt-11-395] Overgeneralized autobiographical memory has been implicated as an important mechanism underlying the pathogenesis of PTSD, and the close connection between overgeneralization in autobiographical memory and in thinking about the future seems to be conducive to the onset and maintenance of the disorder.[@b22-ndt-11-395] To summarize, PTSD is a severe psychiatric disorder, affecting patients' emotions, behavior, social life, and cognitions. With respect to cognitions, memory performance, and more specifically, autobiographical memory performance, is impaired. PTSD is treated pharmacologically and non-pharmacologically. From previous research, we learn that the effect of additional CBT in combination with psychopharmacological treatment is poorly investigated, and in particular that the influence of additional CBT on autobiographical memory has not so far been investigated. Accordingly, the aims of the present study were to investigate the influence of additional CBT on symptoms of PTSD, depression, and anxiety, and on autobiographical memory in patients suffering from PTSD, as compared to a control condition. We hold that the present study has the potential to expand on previous research in that the data from both the case-control design and the study targets should add to the current literature in an important way.

The following two hypotheses were formulated. First, following Hendriksen et al,[@b12-ndt-11-395] Polak et al[@b10-ndt-11-395] and others, we expected improved symptoms of PTSD, depression, and anxiety in the CBT as compared to the control group. Second, following Brown et al[@b21-ndt-11-395] we expected that autobiographic memory performance would be low at baseline and would improve in the treatment as compared to the control group. Additionally, given the lack of previous research, we treated exploratory potential changes in autobiographical memory as a function of domain (semantic and episodic memory) and developmental period (childhood, adulthood, and recent life).

Methods
=======

Procedure
---------

Patients clinically diagnosed as suffering from PTSD (accident-related injuries, cancer, domestic violence) participated in this study. They were all recruited from the Sina Hospital, Mahak (cancer foundation), and from psychiatric and psychological centers in Tehran, Iran. Before entering the study, patients were fully informed about its aims, scope, and procedures and gave written informed consent. Additionally, the local ethics committee approved the study, and the entire study was performed according to the rules laid down in the Declaration of Helsinki.

After a thorough psychiatric interview, all patients were psychopharmacologically treated with SSRIs, neuroleptics, or benzodiazepines ([Table 1](#t1-ndt-11-395){ref-type="table"}). Dosages were individually adapted to patients and kept constant throughout the study in order to achieve and maintain treatment efficacy. Next, patients were randomly assigned either to an intervention or control condition. At the beginning and at the end of the study 10 weeks later, patients completed a series of questionnaires as described in more details below, and experts' ratings were performed in parallel. In addition to the diagnostic interview, both groups had the autobiographical memory interview. After completion of the study, patients in the control condition received the same treatment as that provided for the intervention group. Psychologists and psychiatrists involved in the study and responsible for experts' ratings were not aware of patients' group assignment.

Randomization
-------------

First, a ballot box containing two different colored chips was prepared (20 blue chips for the intervention, and 20 red chips for the control condition). A psychologist (FA) drew chips consecutively and assigned patients to either to the intervention or control condition. FA was also responsible for the psychotherapeutic intervention, though she was not further involved in experts' ratings.

Sample
------

Patients suffering from PTSD and attending the Sina Hospital, Mahak (cancer foundation), and other psychiatric and psychological centers in Tehran, Iran were approached regarding the study. The CONSORT flow chart ([Figure 1](#f1-ndt-11-395){ref-type="fig"}) indicates how many patients were approached, and how many completed the study. Of the 76 patients approached, 40 (52.63%) agreed to participate in the study. Further, 12 patients, who were randomly assigned to the intervention or the control condition, withdraw after randomization and baseline assessment; accordingly, 28 patients started the study. Of these, six (21.43%) were male (mean age: 29.50 years, standard deviation: 4.97) and 22 (78.57%) were female (mean age: 32.23 years, standard deviation: 6.02; *t*\[26\]=1.02, *P*=0.32, *d*=0.496). Please note that to perform the statistical analysis, the intent-to-treat algorithm with the last observation carried forward procedure was performed, and not the per protocol algorithm (see also the "Statistical analysis" section at the end of the "Methods" section).

Inclusion criteria were as follows: 1) a diagnosis of PTSD according to the diagnostic criteria of the *DSM-5*;[@b23-ndt-11-395] and 2) aged between 18 and 45 years. Exclusion criteria were the following: 1) further psychiatric comorbidities such as major depressive disorder, anxiety disorders, substance abuse (alcohol, drugs), psychosis, and personality disorders; 2) women who were pregnant or intending to get pregnant or who were breast-feeding; 3) known physical illness such as heart disease; and 4) patients already undergoing a psychotherapeutic treatment. Patients were also excluded if they decided to withdraw from the study (though without indicating the reasons).

Sample characteristics are reported separately for intervention and control groups in [Table 1](#t1-ndt-11-395){ref-type="table"}.

No differences between the intervention and the control group were observed as regards sociodemographic variables and medications (types and number of medications; for symptoms at baseline for PTSD, depression, and anxiety, [Table 2](#t2-ndt-11-395){ref-type="table"}).

Materials
---------

One questionnaire was employed, which covered demographic variables such as sex, age, civil status, educational level, and current employment.

### Symptoms of PTSD

To assess symptoms of PTSD, the Impact of Event Scale-Revised[@b24-ndt-11-395] questionnaire was employed. It consists of 22 items asking about PTSD symptoms such as avoidance, arousal, and unpleasant thought. Answers are given on 5-point Likert-scales ranging from 0 (never) to 4 (extremely), with higher sum scores reflecting more severe symptoms (Cronbach's alpha =0.92).

### Symptoms of depression

To assess symptoms of depression, the Beck Depression Inventory[@b25-ndt-11-395] questionnaire was employed. It consists of 21 items asking about symptoms of depression such as pessimism and negative thoughts, sadness, reduced incentives, and physiological problems. Answers are given on 4-point Likert-scales ranging from 0 (never) to 3 (extremely), with higher sum scores reflecting more severe symptoms (Cronbach's alpha =0.87).

### Symptoms of anxiety

To assess symptoms of anxiety, the Beck Anxiety Inventory[@b26-ndt-11-395] questionnaire was employed. It consists of 21 items asking about symptoms of anxiety such as worry, anxiety, and physiological problems. Answers are given on 4-point Likert-scales ranging from 0 (never) to 3 (extremely), with higher sum scores reflecting more severe symptoms (Cronbach's alpha =0.92).

### Assessing semantic and episodic memory performance

To assess autobiographical memory, both at baseline and at follow-up, an autobiographical memory interview[@b27-ndt-11-395] was performed. The face-to-face interview consists of 52 items and assesses semantic and episodic memory performance separately for childhood, adulthood, and current life. Typical items are: "Mention three of your childhood friends' or neighbors' full names", "Mention a memory form that course or that job", and "Name a place you visited last year." Trained psychologists and psychiatrists not otherwise involved in the treatment and scoring assessed the semantic and episodic memory performance.

Intervention
------------

The intervention was conceptualized on the basis of Clark and Beck's CBT for the treatment of PTSD[@b28-ndt-11-395] and involved the following procedures. Trained and experienced psychotherapists (psychologists, psychiatrists) not involved in the experts' ratings performed the intervention. Group sessions took place once per week for 60--90 minutes.

### First session

The first session involves establishing a therapeutic relationship with the client: the therapist introduces and explains PTSD, together with its signs and symptoms; brochures are provided about the disease commensurate with the knowledge and educational level of clients. CBT is explained in relation to cognitive features of PTSD, including thoughts, negative beliefs and memories related to the event, negative emotions, and avoidance of trauma-related memories.

### Second session

The second session involves assessment of thoughts and negative beliefs about PTSD and cognitive assessment and rehabilitation of PTSD including correction of erroneous assessments. It also includes modification and cognitive rehabilitation of incorrect assessments.

### Third session

The third session involves cognitive restructuring with a focus on trauma and identification of beliefs and negative evaluations of clients, in cases of injury, and its consequences for explaining the emergence of PTSD.

### Fourth session

The fourth session involves identifying and correcting a patient's faulty thinking and assessment; modifying it through the use of techniques such as reviewing the evidence, analysis of profit and loss, and identifying and modifying cognitive errors; and setting homework.

### Fifth session

The fifth session involves evaluating assignments related to the previous session, including the technique of reviewing the evidence, and explaining new techniques such as loss and profit techniques.

### Sixth and seventh session

The sixth and seventh session involve imagined flooding.

### Eighth and ninth session

The eighth and ninth session involve maladaptive cognitive and behavioral modification techniques through mindfulness training.

### Tenth and closing session

The tenth and closing session include control of emotion through progressive muscle relaxation techniques with breathing regulation.

Individualized health plans were provided in sessions of 1 hour per week in medical centers.

Control condition
-----------------

Once a week, patients in the control condition individually attended the center for a medical check. Further, medication regimen was asked about as well as possible side effects. Patients, however, were free to talk about their current life, concerns, and disorders. On doing so, we kept social contact with the professional hospital staff equal between the intervention and control condition.

Statistical analysis
--------------------

All computations were performed per intention-to-treat with the last-observation-carried-forward (N=20 per group). A series of analyses of variance for repeated measures was performed with the factors "time" (baseline, follow-up) and "group" (intervention versus control group), and the dependent variables of symptoms of PTSD, depression, anxiety, and memory performance. For analyses of variance, effect sizes are indicated with the partial eta squared (η^2^), with 0.059≥η^2^≥0.01 indicating small, 0.139≥η^2^≥0.06 indicating medium, and η^2^≥0.14 indicating large effect sizes. The level of significance was set at *P*≤0.05, and all statistics were processed using SPSS^®^ 20.0 (IBM Corporation, Armonk, NY, USA) for Apple McIntosh^®^.

Results
=======

All descriptive and statistical information (means, standard deviations, *P*-values, effect sizes) are reported in the tables and therefore not repeated in the text.

[Table 2](#t2-ndt-11-395){ref-type="table"} gives a descriptive and statistical overview of symptom-related dimensions separately by group (intervention versus control condition) and time (baseline versus follow-up). Symptoms of both depression and anxiety decreased over time. No group differences were observed. The significant time by group interactions showed that symptoms of depression and anxiety decreased significantly more in the intervention than in the control group.

For PTSDs, total score, avoidance, intrusion, and hyperarousal decreased over time. For hyperarousal, the control group had significantly higher scores than the intervention group. Medium to large effect sizes were observed for the time by group interaction; PTSD scores decreased more over time in the intervention than in the control group ([Table 2](#t2-ndt-11-395){ref-type="table"}).

Autobiographical memory
-----------------------

[Table 3](#t3-ndt-11-395){ref-type="table"} gives a descriptive and statistical overview of symptom-related dimensions separately by group (intervention versus control condition) and time (baseline versus follow-up).

For childhood memory there were no significant changes over time or between groups.

For adult memory (semantic and episodic) scores improved over time but more in the experimental group.

For Recent memory, scores improved over time but improved more in the experimental group.

For positive scores (general), scores increased over time but declined more in the experimental group.

For positive scores (specific), scores increased over time with a greater increase in the experimental group.

Discussion
==========

The key findings of the present study are that additional CBT significantly reduced symptoms of PTSD, depression, and anxiety among a sample of patients suffering from PTSD, as compared to those in a control condition. Moreover, results showed that CBT also improved autobiographical memory over time. The present study adds to the current literature in an important way in demonstrating the advantage of additional non-pharmacological treatments in patients suffering from PTSD; it significantly reduced symptoms and improved memory performance.

Two hypotheses were formulated, and these are now considered in turn. Our first hypothesis was that there would be greater symptom improvements in the intervention than the control group, and this hypothesis was fully supported. Accordingly, the present results are in accordance with a wealth of previous research that has shown a favorable influence of (additional) CBT in the treatment of PTSD, as compared to pharmacological treatment alone.[@b10-ndt-11-395],[@b12-ndt-11-395],[@b17-ndt-11-395] However, the present study expands on previous research in showing that a highly standardized group therapy for ten sessions over a period of 10 weeks improved symptoms of PTSD, depression, and anxiety.

Our second hypothesis was that additional CBT would also improve dimensions of autobiographical memory, and this was broadly supported. Specifically, for autobiographical memory performance for adulthood and the current period of life, the group by time interaction showed that additional CBT led to a significant improvement for semantic memory (but not episodic memory) for adult memory, whereas for recent memory, additional CBT improved episodic memory (but not semantic memory). To the best of our knowledge, similar findings have not so far been reported; accordingly the present study expands upon existing research on PTSD in demonstrating that highly standardized CBT intervention has a positive influence not only on symptoms but also on autobiographical memory.

The present data do not allow any deeper understanding of the underlying cognitive--emotional and neurophysiological mechanisms. However, the following hypotheses are advanced.

As regards the cognitive--emotional changes, we note that the CBT program was specifically targeted at changing and favorably modifying dysfunctional thoughts (see "Methods" section). Accordingly, we assume that patients in the intervention group learned to restructure and positively alter their dysfunctional thoughts and emotions, which as a result reduced symptoms of depression, anxiety, and PTSD. To illustrate, by the second session, patients in the intervention group were already listing their thoughts and negative believes about PTSD and were evaluating the extent to which their behavior was causally associated with the dramatic event leading to PTSD. Likewise they were also evaluating the degree to which they were victims of the event, and the thoughts and feelings associated with it, and, in contrast, to what extent they could learn to manage, modify, and improve their thoughts. Connected to this, we believe that through the CBT intervention, patients became aware of their (unconscious) dysfunctional thoughts and beliefs and learned to evaluate the extent to which their thoughts and feelings were causally linked to the emergence and maintenance of symptoms of depression, anxiety, and PTSD, and that they learned how to cope with their current situation. On the flip side, we note that favorable changes in symptoms and memory were also observed in the control group. Therefore, the present data also show evidence that a mere psychopharmacological treatment leads to improvements both in symptoms and in memory (see also Polak et al,[@b10-ndt-11-395] Ipser et al[@b14-ndt-11-395]).

To explain PTSD from a neuroendocrinologic point of view, it is assumed that an increase in the adrenergic activity of the central nervous system (CNS) is associated with the pathophysiology of PTSD and more specifically with sleep disorders.[@b29-ndt-11-395] In fact, it seems that many of the symptoms of PTSD could be pathophysiologically caused or intensified by an increase in the adrenergic activity of the CNS.[@b29-ndt-11-395],[@b30-ndt-11-395] Such an increase in adrenergic activity can lead to increased secretion of norepinephrine and to elevated responsiveness of receptors to norepinephrine. Accordingly, though highly speculative, we suggest that CBT was able to decrease the adrenergic activity in the CNS. Likewise, though unfortunately not assessed, we believe that CBT was able to improve patients' sleep, which in turn may have led to improvement in symptoms. Indeed, there is a wealth of evidence for a close association between symptoms of depression and anxiety and poor sleep.[@b31-ndt-11-395]--[@b33-ndt-11-395] Accordingly, it is highly conceivable that the sleep of patients in the intervention group improved, and in a sort of positive feedback loop this also ameliorated symptoms of depression, anxiety, and PTSD. Indeed, as regards the association between sleep and PTSD, specific alpha1-receptor-blockers such as prazosin and specific H1-receptor blockers such as hydroxyzine reduce occurrence of nightmares and sleep disturbances among patients suffering from PTSD as compared to a control condition.[@b35-ndt-11-395]

Despite the intriguing results, several limitations warn against overgeneralizing the results. First, the sample size was rather small and there were drop-outs. However, the effect-size calculations which we report are not sensitive to sample sizes. Second, the age range was limited to below 45 years of age; we did this to keep the sample homogeneous and to avoid possible confounders such as age. Nevertheless, we acknowledge, that also enrolling elderly patients would have been advisable, especially given that an emphasis of the study was on autobiographical memory, which would be expected to be worse, and therefore possible more amenable to treatment, in older subjects. Third, sleep was not assessed though there is striking evidence that improved sleep is associated with improvements in symptoms of depression, anxiety, and PTSD.[@b32-ndt-11-395]--[@b34-ndt-11-395] Accordingly, it remains unclear to what extend sleep changes might explain the variance in symptom improvements. Future studies should therefore assess sleep both subjectively and objectively. Fourth, no neuroendocrine assessment was performed; such assessment might have provided more insight into the underlying neuroendocrine mechanisms.[@b36-ndt-11-395],[@b37-ndt-11-395] Fifth, no follow-up assessment was performed; this would have allowed investigation of the longer-term impact of CBT. Last, it is possible that the present pattern of results is due to unassessed variables, which might have biased two or more variables in the same direction.

Conclusion
==========

The present study showed that an additional and highly standardized CBT program had a favorable influence on symptoms of PTSD, depression, and anxiety, and on autobiographical memory among patients suffering from PTSD, as compared to a control group treated pharmacologically only.
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###### 

Descriptive and statistical overview of patients' sociodemographic dimensions and medication at baseline, separately by group (intervention versus control condition)

  N                                                        Group          Statistics     
  -------------------------------------------------------- -------------- -------------- ---------------------------------------
  Age, years (standard deviation)                          32.07 (5.76)   31.21 (6.10)   *t*(38)=0.38, *P*\>0.78
  Sex (male/female)                                        5/15           7/13           *χ*^2^(*df*=1, N=40) =0.85, *P*\>0.35
  Civil status (single/married)                            6/14           7/13           *χ*^2^(1) =0.19, *P*\>0.65
  Medications                                                                            
   Benzodiazepines (yes/no)                                12/8           10/10          *χ*^2^(1) \<1.5, *P*\>0.1
   Antidepressants (yes/no)                                18/2           16/4           *χ*^2^(1) \<1.5, *P*\>0.1
   Neuroleptics (yes/no)                                   6/14           9/11           *χ*^2^(1) \<1.5, *P*\>0.1
   Patients receiving one pharmacologic agent (yes/no)     20/0           20/0           --
   Patients receiving two pharmacologic agents             9/11           11/9           *χ*^2^(1) \<1.0, *P*\>0.1
   Patients receiving three or more pharmacologic agents   3/17           2/18           *χ*^2^(1) \<1.0, *P*\>0.1

###### 

Descriptive and statistical overview of patients' symptom-related dimensions, separated by group (intervention versus control condition) and time (baseline versus follow-up)

                           Time points                                                                                                                                                                                      
  ------------------------ -------------- -------------- -------------- -------------- -------------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------------
  Symptoms of depression   66.43 (5.26)   64.64 (5.58)   38.93 (2.92)   43.64 (4.29)   336.69[\*\*\*](#tfn4-ndt-11-395){ref-type="table-fn"} (0.93) \[L\]   1.63 (0.059) \[S\]                                              6.05[\*](#tfn2-ndt-11-395){ref-type="table-fn"} (0.189) \[L\]
  Symptoms of anxiety      46.29 (6.39)   46.86 (6.81)   42.14 (4.85)   46.21 (5.79)   20.59[\*\*\*](#tfn4-ndt-11-395){ref-type="table-fn"} (0.446) \[L\]   1.01 (0.041) \[S\]                                              11.21[\*\*](#tfn3-ndt-11-395){ref-type="table-fn"} (0.301) \[L\]
  Symptoms of PTSD                                                                                                                                                                                                          
   Total score             66.36 (4.81)   64.00 (5.11)   55.57 (4.77)   63.50 (5.68)   27.80[\*\*\*](#tfn4-ndt-11-395){ref-type="table-fn"} (0.517) \[L\]   3.00 (0.102) \[M\]                                              23.09[\*\*\*](#tfn4-ndt-11-395){ref-type="table-fn"} (0.470) \[L\]
   Avoidance               22.50 (3.92)   22.14 (4.09)   18.79 (2.75)   21.43 (2.90)   8.31[\*](#tfn2-ndt-11-395){ref-type="table-fn"} (0.242) \[L\]        1.16 (0.043) \[S\]                                              3.81 (0.128) \[M\]
   Intrusion               21.71 (3.69)   20.43 (3.34)   18.43 (2.71)   20.64 (2.56)   7.21[\*](#tfn2-ndt-11-395){ref-type="table-fn"} (0.251) \[L\]        0.025 (0.001) \[S\]                                             9.24[\*\*](#tfn3-ndt-11-395){ref-type="table-fn"} (0.262) \[L\]
   Hyperarousal            22.21 (1.63)   22.07 (1.14)   18.38 (2.65)   21.43 (2.17)   22.08[\*\*\*](#tfn4-ndt-11-395){ref-type="table-fn"} (0.459) \[L\]   6.48[\*](#tfn2-ndt-11-395){ref-type="table-fn"} (0.199) \[L\]   11.26[\*\*](#tfn3-ndt-11-395){ref-type="table-fn"} (0.302) \[L\]

**Notes:** Degrees of freedom: always (1, 38)

*P*\<0.05

*P*\<0.01

*P*\<0.001. Effect sizes (η^2^): \[S\] = small effect; \[M\] = medium effect; \[L\] = large effect.

**Abbreviation:** PTSD, post-traumatic stress disorder.

###### 

Descriptive and statistical overview of patients' memory performance, separated by group (intervention versus control condition) and time (baseline versus follow-up)

                     Time points                                                                                                                                                                                           
  ------------------ --------------- -------------- -------------- -------------- -------------------------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------
  Childhood memory                                                                                                                                                                                                         
   Semantic memory   16.18 (2.22)    15.64 (2.51)   16.21 (1.49)   15.79 (2.58)   0.32 (0.01) \[S\]                                                    0.35 (0.0113) \[S\]                                                 0.12 (0.004) \[S\]
   Episodic memory   3.68 (0.95)     4.04 (1.25)    3.85 (0.63)    4.18 (1.14)    1.88 (0.067) \[S\]                                                   0.02 (0.001) \[S\]                                                  0.85 (0.032) \[S\]
  Adult memory                                                                                                                                                                                                             
   Semantic memory   16.280 (1.37)   15.39 (1.90)   17.04 (1.22)   15.05 (1.37)   10.73[\*\*\*](#tfn9-ndt-11-395){ref-type="table-fn"} (0.292) \[L\]   6.03[\*\*\*](#tfn9-ndt-11-395){ref-type="table-fn"} (0.188) \[L\]   4.36[\*\*\*](#tfn9-ndt-11-395){ref-type="table-fn"} (0.144) \[L\]
   Episodic memory   4.10 (1.23)     3.68 (1.29)    4.71 (0.85)    3.89 (1.15)    14.54[\*\*\*](#tfn9-ndt-11-395){ref-type="table-fn"} (0.359) \[L\]   3.33[\*](#tfn7-ndt-11-395){ref-type="table-fn"} (0.113) \[M\]       2.235 (0.079) \[M\]
  Recent memory                                                                                                                                                                                                            
   Semantic memory   17.29 (2.68)    16.9 (3.07)    17.86 (2.21)   16.75 (2.87)   2.96[\*](#tfn7-ndt-11-395){ref-type="table-fn"} (0.102) \[M\]        3.79[\*](#tfn7-ndt-11-395){ref-type="table-fn"} (0.127) \[M\]       0.62 (0.023) \[S\]
   Episodic memory   4.00 (1.30)     3.29 (1.39)    4.57 (0.99)    3.32 (1.34)    9.37[\*\*\*](#tfn9-ndt-11-395){ref-type="table-fn"} (0.265) \[L\]    7.29[\*\*\*](#tfn9-ndt-11-395){ref-type="table-fn"} (0.219) \[L\]   4.39[\*\*](#tfn8-ndt-11-395){ref-type="table-fn"} (0.144) \[L\]

**Notes:** Degrees of freedom: always (1, 38)

*P*\<0.05

*P*\<0.01

*P*\<0.001. Effect sizes (η^2^): \[S\] = small effect; \[M\] = medium effect; \[L\] = large effect.
